Browsing by Author "Basu, A K"
Now showing 1 - 20 of 69
Results Per Page
Sort Options
Item Aerosol lung imaging in chronic obstructive lung disease.(1977-02-01) Chopra, S K; Guleria, J S; Pande, J N; Basu, A KItem Autoerythrocytic sensitization.(1982-08-01) Mukharjee, A; Basu, A KItem Blood groups and diseases.(1971-12-16) Basu, A KItem Carcinoma thyroid in congenital goitre.(1989-05-01) Padhy, A K; Basu, A K; Gopinath, P G; Arunabh,; Sarcar, C; Lata, M; Kapoor, M MItem Cardiac pacing in India (a perspective and prospective study).(1980-11-16) Basu, A KItem Carotid intima media thickness: an independent marker for assessment of macrovascular risk in diabetic patients.(2005-04-22) Basu, A K; Pal, S K; Guha, S; Banerjee, R; Chatterjee, N; Bag, A K; Adhikary, AIn view of the global epidemic of diabetes with India being the hottest reservoir of the disease, it was tried to identify carotid intima media thickness as a surrogate marker for atherosclerosis in diabetic subjects. The study becomes more relevant because diabetes is now considered a disease of the endothelium and a risk equivalent of coronary atherosclerosis (paradigm shift). The study incorporated 41 normotensive patients of diabetes and 31 age and sex matched controls. Plasma glucose and lipid profiles were assessed in all and the carotid intima media thickness was measured. Results were statistically analysed for significance and correlation coefficient between values of plasma glucose and carotid intima media thickness. Results clearly showed that carotid intima media thickness abnormality can pick up atherosclerosis even if the lipid parameters are nearly normal. So it crystallises from this small study that, as a non-invasive test carotid intima media thickness is a better and early predictor of atherosclerosis in diabetic subjects. It also revealed the linear relationship between both fasting and postprandial blood sugar with carotid intima media thickness.Item The changing scenario of diabetes mellitus: from despair to hope.(2004-08-22) Basu, A KItem Chlormerodrin accumulation test a procedure for the assessment of differential renal function.(1971-08-01) Bajaj, J S; Basu, A K; Bhatt, R C; Guleria, J SItem Choledochal cyst in a neonate.(1992-01-01) Basu, A K; Basu, J; Basu, K; Banerjee, SItem Chronic myelogenous leukaemia. The juvenile and adult types. Report of two cases.(1973-07-01) Misra, R C; Basu, A K; Chatterjea, J BItem Clinical medicine and clinical research: an appraisal.(1981-03-01) Basu, A KItem Comparative results of portacaval shunt operations in cirrhosis and non-cirrhotic portal fibrosis of the liver with severe portal hypertension.(1972-06-01) Basu, A K; Laiq, A W; Dhara, P; Das Gupta, R; Chatterjee, AItem Correlation of lipid profile and carotid artery plaque as detected by Doppler ultrasound in ischaemic stroke patients--A hospital-based study.(2006-06-25) Mukherjee, S C; Basu, A K; Bandyopadhyay, R; Pal, S K; Bandopadhyay, D; Mandal, S K; Temsusashi,Stroke is one of the leading causes of morbidity and mortality all over the world. Carotid plaque formation and intima media thickness can be a predictor of ischaemic stroke. In this regard studies from our country, are few and far between. This is a small hospital-based study to look in to this matter. We have assessed the intima media thickness of the common carotid as well as the internal and external carotid arteries by the ultrasound method. The lipid profiles were estimated and correlated with the intima media thickness. Results indicate that in the common as well as in the internal and external carotid arteries, the intima media thickness is a good predictor of ischaemic stroke. This thickness is also well correlated with the lipid levels in blood. Hence this non-invasive method can be used successfully to identify the high risk patients, prone to develop stroke.Item D. C. cardioversion in digitalised patients. A serum digoxin level correlative study.(1974-04-01) Bhatia, M L; Nambiar, A S; Bhalla, B K; Basu, A K; Roy, S BItem Determination of the functional extracellular fluid volume (ECFV) by sodium-24 chloride.(1970-08-01) Rai, K R; Basu, A K; Khanduja, P C; Agarwal, K NItem Effect of chitosan on lipid levels when administered concurrently with atorvastatin--a placebo controlled study.(2005-08-21) Guha, S; Pal, S K; Chatterjee, N; Sarkar, G; Pal, S; Guha, Sharmila; Basu, A K; Banerjee, RIn a placebo controlled trialthe lipid lowering effects of chitosan, a unique dietary fibre, was assessed when given along with atorvastatin 10 mg in patients with chronic coronary heart disease. Altogether 100 patients were studied. They were randomly allocated in two groups of 50 patients each. Patients of group A received atorvastatin 10 mg before dinner plus 2 g/day chitosan in two divided doses. The groupB patients received atorvastatin 10 mg plus placebo. Patients were followed up for a period of 6 weeks. There was significant reduction in mean body weight in group A patients (3.14% versus 1,29% of body weight, p<0.05). There was also a significant rise in HDL cholesterol value (3.8% versus 1.07%, p=0.02) in group A patients. However, there was no significant reduction in the mean values of total cholesterol, LDL cholesterol and triglyceride in the two groups, although group A patients showed marginally lower values.Item Effect of dopamine & amine-oxidase inhibitors in experimental myocardial infarction in rats.(1977-02-01) Kaur, A H; Seth, S D; Kapoor, S C; Basu, A K; Arora, R BItem Effect of perhexilene on 86Rb uptake in experimental myocardial infarction.(1981-08-01) Seth, S D; Gupta, M P; Kaur, A H; Basu, A KItem Effectiveness of heart muscle extract in myocardial necrosis.(1973-03-01) Arora, R B; Basu, A K; Kapoor, S C; Seth, S D; Taneja, VItem Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.(1995-08-01) Adhikari, D; Roy, T B; Biswas, A; Chakraborty, M L; Bhattacharya, B; Maitra, T K; Basu, A K; Chandra, SOBJECTIVES: To assess efficacy and safety of oral iron chelating agent deferiprone (DFP) in patients with beta thalassemia and hemoglobin E-beta thalassemia. DESIGN: Non-randomized study. SETTING: Hematology Out-Patient Department. SUBJECTS: Forty-one patients of beta thalassemia and hemoglobin E-beta thalassemia. INTERVENTIONS: DFP was given to 20 patients, 10 patients of beta thalassemia and 10 with hemoglobin E-beta thalassemia; the rest were taken as controls. RESULTS: A significant fall in serum ferritin was observed in the study group along with rise in urinary iron excretion (p < 0.05). Adverse effects of DFP were nausea and vomiting (30%), significant arthropathy requiring stopping of the drug (30%), and reversible neutropenia in one patient. All these complications could be managed easily with medical supervision and no death or permanent disability was seen. CONCLUSIONS: DFP is an effective and fairly well tolerated oral iron chelating agent. The side effects that occur can be tackled easily if monitored properly.